-transparent.png){kind=logo}
Rabbits were injected either intravenously or intramuscularly with [14C]haem arginate and [59Fe]haem arginate (haem 5 mg kg-1). The main part (80%) of AUCINF of labelled haem was associated with the beta-phase, T1/2 being about 6 h. Only 1% of the haem dose had been taken up by the red blood cells. In contrast, the iron moiety from the haem molecule was effectively utilized. Thirty days post-injection of [59Fe]haem arginate, 40% of the dose after intravenous injection and 60% after intramuscular injection was circulating with the red cells. Radioactivity was shown to concentrate in the liver, where haem is mainly metabolized and eliminated. An accumulation of haem in the adrenals was also evident. Haem itself did not concentrate in the bone marrow, and a negligible amount of radioactivity was recovered from brain, implying a poor penetration of the blood brain barrier.
I B Lindén, and
O Tokola, and
M Karlsson, and
R Tenhunen
January 1976,
The Journal of antibiotics,
I B Lindén, and
O Tokola, and
M Karlsson, and
R Tenhunen
September 1986,
British journal of clinical pharmacology,
I B Lindén, and
O Tokola, and
M Karlsson, and
R Tenhunen
June 1991,
Archives of disease in childhood,
I B Lindén, and
O Tokola, and
M Karlsson, and
R Tenhunen
October 1986,
British medical journal (Clinical research ed.),
I B Lindén, and
O Tokola, and
M Karlsson, and
R Tenhunen
January 1987,
Pharmacology & toxicology,
I B Lindén, and
O Tokola, and
M Karlsson, and
R Tenhunen
January 1975,
Journal of agricultural and food chemistry,
I B Lindén, and
O Tokola, and
M Karlsson, and
R Tenhunen
September 1990,
The British journal of dermatology,
I B Lindén, and
O Tokola, and
M Karlsson, and
R Tenhunen
December 2010,
British journal of pharmacology,
I B Lindén, and
O Tokola, and
M Karlsson, and
R Tenhunen
January 1989,
European journal of haematology,
I B Lindén, and
O Tokola, and
M Karlsson, and
R Tenhunen
May 2001,
Annals of clinical biochemistry,
